Trump EO Aims to Speed Up Psychedelic Research

In a significant move, President Trump's executive order aims to expedite research and access to psychedelic therapeutics, with the FDA Commissioner Marty McCary detailing the new measures. The order directs the FDA to reduce review times for these treatments, with a focus on ensuring safety and efficacy. McCary also announced the first clearance for human trials of a psychedelic compound, ibogaine, and discussed the need for proper supervision and monitoring of potential side effects. Additionally, McCary provided an update on the search for a replacement head of the vaccine program at the FDA.